Abstract

Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.

Original languageEnglish
Article number96
JournalJournal of Biomedical Science
Volume26
Issue number1
DOIs
Publication statusPublished - Dec 5 2019

Fingerprint

Programmed Cell Death 1 Receptor
CTLA-4 Antigen
Chemotherapy
Radiotherapy
Biomarkers
Immunotherapy
Ligands
Molecules
Neoplasms
Therapeutics
Meta-Analysis
Clinical Trials
Drug Therapy

Keywords

  • Cancer immunotherapy
  • Checkpoint inhibitor
  • PD-1 PD-L1 signaling

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. / Wakabayashi, Grace; Lee, Yu Ching; Luh, Frank; Kuo, Chun Nan; Chang, Wei Chao; Yen, Yun.

In: Journal of Biomedical Science, Vol. 26, No. 1, 96, 05.12.2019.

Research output: Contribution to journalReview article

Wakabayashi, Grace ; Lee, Yu Ching ; Luh, Frank ; Kuo, Chun Nan ; Chang, Wei Chao ; Yen, Yun. / Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. In: Journal of Biomedical Science. 2019 ; Vol. 26, No. 1.
@article{868c35ab3815472789a25fb4666767ac,
title = "Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway",
abstract = "Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.",
keywords = "Cancer immunotherapy, Checkpoint inhibitor, PD-1 PD-L1 signaling",
author = "Grace Wakabayashi and Lee, {Yu Ching} and Frank Luh and Kuo, {Chun Nan} and Chang, {Wei Chao} and Yun Yen",
year = "2019",
month = "12",
day = "5",
doi = "10.1186/s12929-019-0588-8",
language = "English",
volume = "26",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

AU - Wakabayashi, Grace

AU - Lee, Yu Ching

AU - Luh, Frank

AU - Kuo, Chun Nan

AU - Chang, Wei Chao

AU - Yen, Yun

PY - 2019/12/5

Y1 - 2019/12/5

N2 - Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.

AB - Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.

KW - Cancer immunotherapy

KW - Checkpoint inhibitor

KW - PD-1 PD-L1 signaling

UR - http://www.scopus.com/inward/record.url?scp=85075998495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075998495&partnerID=8YFLogxK

U2 - 10.1186/s12929-019-0588-8

DO - 10.1186/s12929-019-0588-8

M3 - Review article

C2 - 31801525

AN - SCOPUS:85075998495

VL - 26

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 96

ER -